[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editor's Correspondence
November 26, 2001

Pharmaceutical Manufacturer Sponsorship and Drug Information

Arch Intern Med. 2001;161(21):2625-2626. doi:

The recent article "Dose Discrepancies Between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events"1 is timely and provocative. As clinicians involved with the education of medical practitioners, we frequently discuss the limitations of the Physicians' Desk Reference (PDR). Inaccuracies in PDR overdose management guidelines have been described elsewhere.2 Although some practitioners are aware of the PDR's limitations, we believe that most clinicians have difficulty appreciating the consequences of these information discrepancies. This is exemplified by the persistent high utilization of the PDR despite the availability of alternative references, as pointed out by the authors.

First Page Preview View Large
First page PDF preview
First page PDF preview